All News

DSM Pharmaceutical Products opens a cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.

FDA releases a strategic plan and issues a proposed notification rule to improve prevention and resolution of drug shortage problems.

A new report details FDA's role and responsibilities in personalized medicine.

Jeremy Levin, CEO and president of Teva Pharmaceutical Industries steps down , and interim successor named.

Hospira opens a new quality and analytical testing laboratory at its Rocky Mount, North Carolina plant.

Novartis files Citizen Petition with FDA to maintain naming policy for all biologics to help ensure patient safety.

WuXi PharmaTech has completed a cell culture capacity expansion, including two 2000 L disposable bioreactors.

GSK and the Gates Foundation will invest a combined $1.8 million in early stage research into vaccine thermostability.

Zhoydro ER is the first drug to have updated labeling now required for all ER/LA opioid analgesics.

SGS Life Science Services opens a Center of Excellence for Biophysical Analysis in the UK.

Big pharma companies Novartis, Amgen, and Bristol-Myers Squibb announce positive third-quarter 2013 results.

Beckman Coulter Life Sciences combines its particle characterization business with the Hach Company particle counting business.

Amarin cuts staff in half after an FDA committee rejects its product label expansion.

FDA has awarded 15 grants totaling more than $14 million to boost the development of products for patients with rare diseases.

FDA is seeking a permanent injunction against a dietary supplement manufacturer following the company?s repeated distribution of unapproved drugs and adulterated dietary supplements.

Novozymes Biopharma will collaborate with Almac to provide a combined service for drug development applications.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

The FDA grants Cornerstone Pharmaceuticals orphan drug designation for CPI-613 for the treatment of myelodysplastic syndrome.

The US Pharmacopeial Convention posted for public comments on its revisions to the USP Medicare Model Guidelines, which are posted for a 30-day public comment period, beginning Oct. 1, 2013.

PhRMA reports 452 new medicines are in development for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders.

Sartorius and BD Diagnostics plan to collaborate on ready-to-use, prefilled media products for microbiological applications.

Governor Jerry Brown cites physician notification requirements for dispensing biosimilars as premature in the absence of FDA specifications for interchangeability.

Genzyme will build a facility in Massachusetts to expand purification capacity for Fabrazyme (agalsidase beta).

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

Roche plans multimillion biologic manufacturing expansions in California, Switzerland, and Germany.

The generic-drug manufacturer Teva Pharmaceutical Industries plans to cut 10% of its workforce.

Vetter is investing $100 million to expand filling capacity in Germany and the United States.

Janssen Pharmaceuticals collaborates with CureVac and DCPrime in vaccines.

ABC Laboratories plans to move operations of its subsidiary, Morse Laboratories, based in California, to Missouri.